Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-06-22

Clinical Trial Update: Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia [Phase 3]

View source ↗

Summary

This trial update summarizes results from a Phase 3 study evaluating the clinical benefit of SEROQUEL XR in adults with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SEROQUEL XR (Quetiapine)

Snippet

Sponsor: AstraZeneca | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2012-06-22